ReviewExpert opinion on therapeutic targets2022
Neuropathic ocular surface pain: Emerging drug targets and therapeutic implications.
Review in Expert opinion on therapeutic targets, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Emerging Therapeutic Modalities and Pharmacotherapies in Neuropathic Pain Management: A Systematic Review and Meta-Analysis of Parallel Randomized Controlled Trials.Pain research & management · 2024Pooled it
- Misoprostol in Refractory Neuralgic Pain: From Clinical Neurology to an EP-Receptor Hypothesis of Pharmacodynamic Persistence.International journal of molecular sciences · 2026Review
- Current and Developing Therapeutics for Dry Eye Disease: Targeting Ion Channels.Current issues in molecular biology · 2026Review
- Emerging Technologies in Corneal Nerve Evaluation for Dry Eye and Ocular Surface Disease: A Review.Journal of clinical medicine · 2026Review
- Corneal confocal microscopy in fibromyalgia syndrome: small fiber neuropathy, and treatment outcomes.Eye (London, England) · 2026Article
- Transcriptomic Analysis in a Model of Aniridia-Associated Keratopathy for Target Discovery and Evaluation of Duloxetine Therapy.Investigative ophthalmology & visual science · 2026Article
- Prolonged aftersensations to thermal noxious stimulation as a screening tool for central contributions to chronic ocular pain.The journal of pain · 2026Article
- Focused Narrative Review: Non-Pharmacological, Noninvasive Neurostimulation or Neuromodulation Treatment of Ocular Neuropathic Pain.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Long-Term Clinical and Molecular Changes in Dry Eye Disease and Chronic Ocular Pain.International journal of molecular sciences · 2025Article
- P2X4 Receptor Antagonist Ameliorates Ocular Pain in Rats After Lacrimal Gland Removal.Translational vision science & technology · 2025Article
- Microstructural alterations of the trigeminal ganglion in chronic ocular surface pain patients: A diffusion MRI study.NeuroImage · 2025Article
- Navigating the Dry Eye Therapeutic Puzzle: A Mechanism-Based Overview of Current Treatments.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Impact of botulinum toxin type A on ocular pain with neuropathic features.The ocular surface · 2025Article
- Validation of the Ocular Pain Assessment Survey Instrument With Rasch Analysis.Translational vision science & technology · 2025Article
- The influence of amniotic membrane proteins on corneal regeneration when delivered directly or using hydrogel platforms.Frontiers in medicine · 2025Article
- Corneal neuropathic pain: a review to inform clinical practice.Eye (London, England) · 2024Review
- Review
- Corneal Neuropathic Pain: A Patient and Physician Perspective.Ophthalmology and therapy · 2024Article
- Electroacupuncture for mild-to-moderate dry eye: study protocol for a multicentre, randomised, single-blind, sham-controlled trial.BMJ open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionDysfunction at various levels of the somatosensory system can lead to ocular surface pain with a neuropathic component. Compared to nociceptive pain (due to noxious stimuli at the ocular surface), neuropathic pain tends to be chronic and refractory to therapies, making it an important source of morbidity in the population. An understanding of the options available for neuropathic ocular surface pain, including new and emerging therapies, is thus an important topic. AREAS COVERED: This review will examine studies focusing on ocular surface pain, emphasizing those examining patients with a neuropathic component. Attention will be placed toward recent (after 2017) studies that have examined new and emerging therapies for neuropathic ocular surface pain. EXPERT OPINION: Several therapies have been studied thus far, and continued research is needed to identify which individuals would benefit from specific therapies. Gaps in our understanding exist, especially with availability of in-clinic diagnostics for neuropathic pain. A focus on improving diagnostic capabilities and researching gene-modulating therapies could help us to provide more specific mechanism-based therapies for patients. In the meantime, continuing to uncover new modalities and examining which are likely to work depending on pain phenotype remains an important short-term goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.